BioLineRx (NASDAQ:BLRX) Lifted to “Hold” at StockNews.com

BioLineRx (NASDAQ:BLRX – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

BLRX opened at $1.27 on Friday. BioLineRx has a fifty-two week low of $1.20 and a fifty-two week high of $3.73. The firm’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.99. The company has a market capitalization of $60.55 million, a P/E ratio of -1.74 and a beta of 2.04.

BioLineRx (NASDAQ:BLRX – Get Rating) last posted its quarterly earnings results on Wednesday, March 16th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, analysts forecast that BioLineRx will post -0.56 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC acquired a new stake in BioLineRx during the third quarter worth $33,000. PVG Asset Management Corp boosted its stake in shares of BioLineRx by 109.6% in the 4th quarter. PVG Asset Management Corp now owns 160,360 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 83,850 shares in the last quarter. Morgan Stanley boosted its stake in shares of BioLineRx by 5.9% in the 3rd quarter. Morgan Stanley now owns 240,128 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 13,306 shares in the last quarter. LPL Financial LLC boosted its stake in shares of BioLineRx by 11.4% in the 4th quarter. LPL Financial LLC now owns 73,576 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of BioLineRx by 212.1% in the 3rd quarter. Geode Capital Management LLC now owns 32,026 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 21,763 shares in the last quarter. Hedge funds and other institutional investors own 5.23% of the company’s stock.

BioLineRx Company Profile (Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Featured Articles